{"classes":[{"categories":[{"measurements":[{"comment":"Upper bound not reached for 95% CI","groupId":"OG000","lowerLimit":"9","upperLimit":"NA","value":"19"}]}],"title":"colon cancer"},{"categories":[{"measurements":[{"comment":"Upper bound not reached for 95% CI","groupId":"OG000","lowerLimit":"14","upperLimit":"NA","value":"16"}]}],"title":"appendiceal cancer"},{"categories":[{"measurements":[{"comment":"Median not reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Mesothelioma"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The length of time during and after the treatment that patients remain alive with disease that does not progress. Per RECIST 1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","dispersionType":"95% Confidence Interval","groups":[{"description":"α DC1 vaccine\n\nand\n\nChemokine Modulatory Regimen:\n\nCelecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \\& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\\^2 or 20 MU/m\\^2 (T-Fri)","id":"OG000","title":"α DC1 Vaccine + Chemokine Modulatory Regimen"}],"paramType":"MEDIAN","populationDescription":"Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery and response to treatment.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}